PINK1 and PARIS in Parkinson’s

news July 04 2017

Parkinson’s disease (PD) is one of the most well-known neurodegenerative disorders among the 600+ disorders afflicting the nervous system. Progressive loss of dopaminergic neurons (DAs) in the substantia nigra is a contributing factor in the development of PD. A recent study by Lee et al, has demonstrated that PINK1 and Parkin, two proteins commonly mutated in PD, work collaboratively to regulate the steady-state levels of PARIS to ensure DA neuron survival. Inactivation of PINK1 or Parkin was shown to lead to improper clearance of PARIS, DA neuron loss and neurodegeneration. Learn more about the reagents BioLegend offers to study these integral PD-associated pathways.

Learn more about Parkinson’s Disease

Description Clone Reactivity Applications
Purified anti-PARIS (ZNF746) Antibody N196/16 Human, Mouse, Rat WB, IHC
Purified anti-Parkin Antibody Prk 109 Human, Mouse ELISA, WB, IHC
Purified anti-Parkin Antibody Prk 8 Human, Mouse ELISA, WB, IHC
Purified anti-PINK1 Antibody N4/15 Human, Mouse, Rat WB
Purified anti-PINK1 Antibody DU46-1.1 Human ELISA, WB, IHC, IP

 

Featured Products
LEGEND MAX™ Human α-Synuclein ELISA Kit with Pre-coated Plate

Antibodies for PD-Related Proteins 
α-Synuclein, aggregated
α-Synuclein, 34-45
LRRK2
DJ-1 (PARK7)